Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD207 CAR-T in R/R Langerhans Cell Histiocytosis
NCT05477446Phase 1Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Oct 2022
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD207 CAR-T cells in Langerhans cell histiocytosis (LCH), sponsored by Beijing Friendship Hospital. Primary endpoints: Overall Response Rate at 2 years and Incidence and Severity of Adverse Events at 2 years. Status: unknown.
02
Drugs
CD207 CAR-T cells
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT05477446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477446.